SCHEMBL6480798

SCHEMBL6480798

N#Cc1c(N(C(=O)c2ccc3c(c2)OCO3)C(=O)c2ccc3c(c2)OCO3)nc2ccccc2c1NCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
GAA P10253 2/20 0.48
KDM4E B2RXH2 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KMT2A Q03164 6/20 0.48
MEN1 O00255 5/20 0.48
MAPK1 P28482 4/20 0.48
HSD17B10 Q99714 4/20 0.48
LMNA P02545 4/20 0.48
CYP1A2 P05177 3/20 0.48
CYP3A4 P08684 3/20 0.48
CYP2D6 P10635 3/20 0.48
CYP2C19 P33261 3/20 0.48
TP53 P04637 2/20 0.48
HIF1A Q16665 1/20 0.48
HPGD P15428 2/20 0.45
MAPT P10636 3/20 0.45
ALOX12 P18054 1/20 0.45
TSHR P16473 4/20 0.43
USP2 O75604 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488993 0.89 ALDH1A1 (0.51) ALDH1A1GAAKDM4ESMN1; SMN2KMT2A
SCHEMBL6479836 0.85 ALDH1A1 (0.54) ALDH1A1GAAKDM4ESMN1; SMN2KMT2A
SCHEMBL5224357 0.83 KMT2A (0.47) ALDH1A1KMT2AMEN1MAPK1HSD17B10
SCHEMBL6478489 0.83 LMNA (0.45) ALDH1A1GAAKDM4ESMN1; SMN2KMT2A
SCHEMBL5220504 0.81 KMT2A (0.48) ALDH1A1SMN1; SMN2KMT2AMEN1MAPK1
SCHEMBL5460979 0.81 ADORA3 (0.46) ALDH1A1GAAKDM4ESMN1; SMN2KMT2A
SCHEMBL6491520 0.77 KMT2A (0.46) ALDH1A1GAAKDM4ESMN1; SMN2KMT2A
SCHEMBL940614 0.76 ALDH1A1 (0.44) ALDH1A1GAAKDM4ESMN1; SMN2KMT2A
SCHEMBL6487647 0.74 MEN1 (0.54) ALDH1A1GAAKDM4ESMN1; SMN2KMT2A
SCHEMBL5224004 0.74 ADORA3 (0.42) ALDH1A1GAAKDM4ESMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390349-B1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SA (FR) 2012-07-25 EP disclosed
US-6969723-B2 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI - AVENTIS (FR) 2005-11-29 US disclosed
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI (FR) 2004-09-23 US disclosed
WO-2002096879-A9 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SYNTHELABO (FR) 2003-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands ADORA3, ADORA1, ADORA2A ALDH1A1 273/4885GAA 3329/4885KDM4E 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.